HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NPCE

NeuroPace, Inc. (NASDAQ)

Healthcare — Medical Devices

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

None 8 analysts
$15.77
$-0.12 (-0.76%)
Target: $20.00 (26.8%)
Sign in to add NPCE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$537.66M
P/E Ratio (TTM)-
Forward P/E-53.05
EPS (TTM)$-0.65
Dividend Yield-
Profit Margin-21.67%
Revenue Growth-2.00%
ROE-111.38%
Debt/Equity487.49
Recommendation None
Analyst Target$20.00
Analysts8
Indexes NASDAQ

Technical Indicators

RSI (14)50.8
Beta1.88
SMA 20-
SMA 40-
52-Week High$19.60
52-Week Low$7.56
50-Day Avg$16.36
200-Day Avg$14.53
Avg Volume183.8K
Volume187.6K

Performance Analysis

NEUTRAL

NPCE presents a mixed picture with both positive and negative indicators.

~ Trading at 68% of its 52-week range.
~ RSI at 50.8 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- Revenue declined 2.0% year-over-year.
- Operating at a loss with -21.7% margin.
~ Wall Street consensus is "none" from 8 analysts.
+ Average analyst target of $20.00 implies 26.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report